How to Grow a Weight Loss/GLP-1 Practice as a Prescriber

If you’re a psychiatrist or psychiatric nurse practitioner watching the GLP-1 craze unfold, you’ve probably asked yourself: Should I be offering this in my practice?

It’s a fair question. On one hand, you went into psychiatry to treat mental health, not run a weight-loss clinic. On the other, you’re seeing the same thing I am: patients asking about Ozempic, medication-induced weight gain becoming a barrier to treatment adherence, and an entire telehealth industry making millions off these drugs while you refer patients elsewhere.

Here’s the reality: the GLP-1 weight-loss market is exploding, and psychiatrists are uniquely positioned to capture a piece of it — not by abandoning your core practice, but by integrating metabolic care where it naturally overlaps with mental health.

Let me break down what this opportunity actually looks like, who it’s for, and whether it makes sense for your practice.

The Market Reality: Demand Is Real and Growing

The numbers tell a clear story. By 2024, an estimated 18 million U.S. adults (7%) were using GLP-1 drugs for weight loss, with surveys showing another 14% interested in trying them. The weight-loss telehealth market hit $6.9 billion in 2023, growing 8%+ annually as patients flooded online platforms seeking prescriptions.

This isn’t a fad. Obesity prevalence remains above 30% in every U.S. state, affecting roughly 1 in 3 adults. Traditional weight-loss approaches have failed most of these patients. Now, for the first time in decades, we have medications that produce meaningful, sustained weight loss — an average of 15% body weight in clinical trials, with real-world results closer to 8-12%.

What does this mean for psychiatrists? You already treat many of these patients. They’re the ones who gained 40 pounds on Abilify. The ones with binge eating disorder who’ve tried every diet. The ones whose depression improved on mirtazapine but who now avoid mirrors. Many of them are already asking you about GLP-1s, or they’re quietly seeking them elsewhere while continuing psychiatric treatment with you.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Why Psychiatrists Are Actually Well-Positioned for This

Most weight-loss clinics treat obesity as a purely metabolic problem. You know better. You understand that:

• Weight and mental health are inseparable. Depression, anxiety, ADHD, and eating disorders all influence eating behavior and metabolism. Research shows patients with psychological distress are more likely to seek and use GLP-1 medications.

• Medication side effects are psychiatric territory. Antipsychotics, mood stabilizers, some antidepressants — these are major drivers of weight gain. You’re already managing the medications that created the problem; why not offer the solution?

• Behavioral change requires more than a prescription. The telehealth mills prescribe GLP-1s with minimal follow-up. You have the training to address the emotional eating, body image issues, and lifestyle factors that determine whether patients succeed long-term.

Dr. Alex Spencer, a metabolic psychiatrist, argues that integrating GLP-1 prescribing into psychiatric care ‘makes complete sense’ because metabolic and mental health systems are biologically intertwined. GLP-1 agonists work on brain receptors involved in appetite and reward, overlap with psychiatric pathways, and emerging data suggests they may even improve mood and reduce addictive behaviors in some patients.

From a clinical standpoint, you’re not practicing outside your scope — you’re practicing comprehensive psychiatry that addresses the whole patient.

The Business Case: Real Revenue, But Be Smart About It

Let’s talk economics, because if you’re going to add a service line, it needs to make financial sense.

Average patient value in weight management: Most telehealth weight-loss patients spend about $600-800 per year on services (visit fees, program subscriptions, coaching). That’s separate from the medication cost itself, which patients either pay out-of-pocket ($1,000+/month for brand-name) or get covered by insurance.

Your revenue model would likely look like this:

• Initial consultation: $200-300 (60 minutes, comprehensive eval including psychiatric assessment)
• Monthly follow-ups: $100-150 each (15-30 minutes for monitoring, adjustments, side effect management)
• Optional add-ons: Nutritional coaching, body composition tracking, or therapy for emotional eating (additional revenue streams)

If you treat even 10 active weight-loss patients, that’s roughly $12,000-15,000 in annual revenue per 10 patients — and these appointments are often easier to fill than traditional therapy slots because they’re shorter and outcome-focused.

But here’s the critical part: Don’t expect to build this cheaply through DIY marketing.

The Real Cost of Patient Acquisition (And Why Platforms Make Sense)

Many psychiatrists see the GLP-1 boom and think: ‘I’ll just add it to my website and run some Google Ads.’ Let me save you some money and frustration: that rarely works cost-effectively.

Here’s why. Acquiring a qualified psychiatric patient through DIY digital marketing typically costs $200-500+ per patient when you factor in all the hidden costs:

• Google Ads for weight loss keywords are brutal. Terms like ‘GLP-1 doctor’ or ‘Ozempic prescription’ cost $15-40+ per click, and most clicks don’t convert to appointments. A realistic cost per booked patient through PPC is $300-400+.

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow. You need ongoing content creation, technical optimization, and backlink building. Most solo providers don’t have the expertise, time, or budget to do this right.

• Directory listings are crowded and expensive. Psychology Today charges monthly fees and you’re competing with hundreds of other providers on the same search page. Zocdoc charges $35-100+ per booking plus monthly subscription fees.

• Staff time and failed leads add up. Someone needs to answer inquiries, qualify leads, handle no-shows from cold traffic, and test campaigns. When you add up the agency fees, ad spend, staff hours, and failed experiments, the true cost per patient acquisition often exceeds $400.

Most independent providers vastly underestimate these costs because they don’t track them properly. They see ‘$50/month for SEO tools’ and think it’s cheap, forgetting about the $3,000/month they’re paying a marketing consultant or the 10 hours their admin spent fielding unqualified leads.

The platform alternative: This is where Klarity Health’s model becomes relevant. Instead of gambling thousands on marketing channels with uncertain ROI, you pay a standard fee per qualified patient lead who books with you. Think of it like Zocdoc’s pay-per-appointment model, but with key advantages:

• No upfront marketing spend or monthly subscriptions — you only pay when patients actually book
• Pre-qualified patients matched to your specialty and availability (not random clicks)
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow (broader reach)
• You control your schedule — scale up or down based on capacity

The math is simple: Would you rather spend $3,000-5,000/month on marketing with uncertain results, or pay a predictable per-appointment fee only when you see patients? For most psychiatrists — especially those starting out in weight management or already busy with existing patients — the platform model removes risk entirely.

The State-by-State Opportunity (And Obstacles)

Your growth strategy will depend heavily on where you’re licensed. Here’s what matters:

California: By 2026, experienced NPs have full practice authority (no physician supervision needed after 3+ years). Medi-Cal covers GLP-1 obesity medications, which drove $1.4 billion in spending in 2024 — that’s thousands of covered patients. If you’re a PMHNP in CA, you can build an independent practice. If you’re a psychiatrist, you can hire NPs to scale.

Texas: High obesity rates (35%+) but restrictive NP laws (physician supervision required). Texas Medicaid covers Wegovy partially. The upside? Huge underserved patient population. The challenge? You’ll need a supervising MD if you’re an NP, and marketing costs are high due to competition.

Florida: Unique in that out-of-state providers can treat FL patients via a simple telehealth registration (no full FL license needed for some situations). But Florida Medicaid does not cover GLP-1 for obesity, so most patients are cash-pay. Strong demand from aging population and aesthetic/wellness markets in South Florida.

New York: Full practice authority for NPs with 3,600+ hours experience. Dense NYC market with high competition, but also high willingness to pay for premium services. NY Medicaid doesn’t cover obesity meds, so target commercially insured or affluent self-pay patients.

Pennsylvania: NPs still need physician collaboration (no independent practice yet). But PA Medicaid does cover Wegovy and Zepbound, and spent nearly $300 million on GLP-1s in 2024. This means insured patient demand is strong. Partner with an MD if you’re an NP, or capitalize on covered populations if you’re a psychiatrist.

Illinois: NPs can achieve full practice authority after 4,000 hours + training. Illinois Medicaid currently doesn’t cover obesity drugs (though legislation has been proposed). Focus on employer-insured patients in Chicago suburbs or offer competitive cash pricing.

One federal wrinkle: DEA rules on controlled substances via telehealth. If you plan to prescribe phentermine (Adipex) alongside GLP-1s, the COVID-era telemedicine flexibility expires December 31, 2025. After that, new patients need at least one in-person visit before you can prescribe Schedule IV appetite suppressants remotely. GLP-1 drugs are not controlled, so they remain telehealth-friendly nationwide.

What Patients Are Actually Searching For

Understanding patient search behavior helps you meet them where they are:

• They search for medications, not providers. Top queries: ‘How to get Ozempic for weight loss’ (113,000+ clicks/month), ‘Ozempic prescription online,’ ‘Wegovy near me.’ Patients want the drug first, the provider second. Make sure your online presence makes it clear you prescribe GLP-1s.

• They want convenience and speed. Searches like ‘online weight loss clinic same day’ or ‘telehealth Wegovy’ reflect a retail mindset. If you offer telehealth, advertise quick appointment availability.

• They’re cost-conscious. Many search ‘cheap Wegovy alternative’ or ‘compounded semaglutide clinic.’ If you work with compounding pharmacies or help patients navigate insurance, emphasize that.

• Some seek privacy. Patients with weight stigma or past trauma search for ‘telemedicine weight loss no judgment’ or ‘discreet GLP-1 prescription.’ Psychiatric providers have a natural advantage here — you’re trained in empathy and non-judgmental care.

Smart Marketing for Weight Management Services

If you decide to add GLP-1 prescribing, here’s how to grow efficiently:

1. Define your niche clearly. Don’t market to ‘everyone who wants to lose weight.’ Target women 40+ with medication-related weight gain or patients with binge eating and obesity or professionals with stress-related weight issues. Specificity increases conversion.

2. Invest in content marketing, not just ads. Educational blog posts (‘Can a psychiatrist help with weight loss?’ ‘Managing Abilify weight gain with GLP-1s’) rank in search for years and cost nothing after initial creation. Content marketing generates 3× more leads than paid ads at 62% lower cost.

3. Build an email list. Offer a free guide (‘5 Things to Know Before Starting Ozempic’) in exchange for emails. Email marketing delivers an average $42 return per $1 spent — higher ROI than any other channel.

4. Use paid ads strategically. If you run Google or Facebook ads, target niche keywords (not the $40/click ones big telehealth companies dominate). Maybe ‘psychiatrist for weight loss [City]’ or ‘mental health and obesity treatment.’ Drive traffic to valuable content, not just a ‘Book Now’ page.

5. Encourage referrals and reviews. Happy patients are your best marketers. Politely ask for referrals and online reviews. Many prospective patients read Google reviews before booking — a strong reputation matters.

6. Track metrics obsessively. Know your cost per lead, conversion rate (leads to patients), patient lifetime value, and ROI per marketing channel. If something isn’t working (Facebook ads with lots of clicks but no bookings), cut it and double down on what converts.

7. Stay compliant. Avoid ‘lose 30 lbs in 30 days’ promises. Use disclaimers (‘individual results vary’). The FTC and state medical boards scrutinize weight-loss advertising — your credibility as a licensed provider is your biggest asset, so protect it.

Should You Do This?

Not every psychiatrist should offer weight management. Here’s who it makes sense for:

Good fit if:

• You already see patients with medication-induced weight gain
• You treat eating disorders, ADHD, or conditions with metabolic overlap
• You’re comfortable managing medication side effects (nausea, GI issues)
• You want to differentiate your practice and add a revenue stream
• You’re open to telehealth (most GLP-1 patients prefer virtual)
• You have (or can get) training in obesity medicine basics

Skip it if:

• You’re maxed out with existing patients and hate the idea of ‘one more thing’
• You view weight as outside your scope and have no interest in learning
• You’re uncomfortable with the retail/consumer aspect of weight loss services
• Your state has burdensome regulations that make it impractical (e.g., you’re an NP in a restricted state with no MD partner)

Final Thought: Metabolic Psychiatry Isn’t a Gimmick

Some psychiatrists worry that offering GLP-1 prescriptions is ‘selling out’ or chasing trends. I’d argue the opposite. Ignoring your patients’ metabolic health is the mistake.

When a patient gains 50 pounds on Seroquel and stops taking it, that’s a treatment failure — but it’s preventable. When someone with binge eating disorder continues to struggle because you only offer therapy and don’t address the biological drivers, you’re leaving tools on the table.

The GLP-1 boom presents a rare alignment: a massive patient need, effective medications, and a service that genuinely complements psychiatric care. The market will attract plenty of entrepreneurs and telehealth companies happy to treat weight loss as a transaction. You can offer something better: comprehensive care that treats the mind and body as the integrated system they actually are.

Whether you do this independently, join a platform like Klarity Health to handle patient acquisition, or simply refer patients to trusted colleagues, the key is making an informed decision based on your practice goals and patient needs — not fear of being left behind or jumping on a bandwagon.

The opportunity is real. Whether you take it is up to you.

Frequently Asked Questions

Is it legal for psychiatrists to prescribe GLP-1 medications for weight loss?

Yes. Psychiatrists are licensed physicians who can prescribe medications within their scope of competence. GLP-1 agonists like semaglutide (Wegovy) are FDA-approved for obesity treatment. As long as you obtain proper informed consent, monitor patients appropriately, and stay within professional guidelines, prescribing GLP-1s is legal. Some psychiatrists pursue additional training in obesity medicine to strengthen their expertise.

Do I need special certification to offer weight management services?

No formal certification is required, but additional training is recommended. Organizations like the Obesity Medicine Association offer board certification in obesity medicine (diplomate certification) which involves coursework and an exam. At minimum, familiarize yourself with GLP-1 prescribing guidelines, contraindications, side effect management, and lifestyle counseling for obesity. Many CME courses cover these topics.

What if I’m a psychiatric nurse practitioner — can I prescribe GLP-1s independently?

It depends on your state. In full practice authority states (California, New York, Illinois for experienced NPs), you can prescribe independently. In restricted states (Texas, Pennsylvania, Florida for psych NPs), you need a collaborating physician agreement. Check your state board of nursing regulations. GLP-1 drugs are not controlled substances, so they’re easier to prescribe via telehealth than stimulants or benzodiazepines.

How much can I realistically earn from adding weight-loss services?

If you see 10-15 weight-loss patients per month with initial consults at $250 and monthly follow-ups at $125, that’s roughly $15,000-20,000 in additional annual revenue. Some practices charge more for comprehensive programs (nutrition counseling, body composition analysis) and see higher numbers. The key is balancing volume with quality of care — don’t overextend yourself.

What about insurance reimbursement?

Insurance coverage varies. Many commercial plans now cover GLP-1 medications for obesity (as of 2024, 52% of large employers offered coverage). Medicaid coverage is state-dependent: California, Pennsylvania, and a few others cover Wegovy/Zepbound; most states don’t. Medicare currently doesn’t cover obesity meds, but pilot programs may change that by 2027. For your visit fees, bill using obesity diagnosis codes (E66.x) and appropriate CPT codes for evaluation and management.

Do patients actually stay on these medications long-term?

Adherence is challenging. Real-world data shows about 50% of patients discontinue GLP-1s within the first year, often due to cost, side effects, or achieving their goal weight. However, adherence is improving as shortages ease and insurance coverage expands. Practices that offer behavioral support, nutrition counseling, and close monitoring see better retention. Emphasize to patients that this is likely a long-term medication (like antidepressants) — stopping often leads to weight regain.

How do I handle patients who want GLP-1s but don’t meet criteria?

Use evidence-based guidelines. FDA approval covers patients with BMI ≥30, or BMI ≥27 with weight-related comorbidities (hypertension, diabetes, sleep apnea, etc.). If a patient with BMI 24 wants to lose ‘vanity weight,’ that’s off-label and higher risk with limited benefit. Have a clear policy and explain it kindly. You can offer alternative support (therapy for body image, nutrition consult) but don’t compromise medical judgment for cash.

What are the biggest side effects I need to watch for?

GI issues (nausea, vomiting, diarrhea, constipation) are most common, especially during dose titration. Slow titration and anti-nausea strategies help. Rare but serious: pancreatitis (watch for severe abdominal pain), gallbladder disease, and thyroid C-cell tumors (contraindicated in patients with personal or family history of medullary thyroid cancer or MEN2). Also monitor for worsening depression or suicidal ideation, though studies suggest GLP-1s don’t increase these risks and may improve mood in some patients.

Can I combine GLP-1s with other psychiatric medications?

Generally yes, but monitor closely. Some psychiatric meds (antipsychotics, mood stabilizers, certain antidepressants) cause weight gain or metabolic changes that you’re trying to counteract. There’s no major pharmacokinetic interaction, but watch for additive GI side effects if combining with medications that cause nausea. Also consider whether the GLP-1 reduces appetite so much that patients forget to take other meds — adherence matters.

How do I compete with big telehealth companies that spend millions on ads?

You don’t compete on their terms. They win on volume and convenience. You win on quality, integration, and trust. Position yourself as the provider who treats the whole person, not just writes prescriptions. Emphasize your psychiatric expertise and holistic approach. Lean into local SEO, professional referrals, and word-of-mouth. Partner with platforms like Klarity Health that handle patient acquisition so you can focus on care, not marketing budgets.

Is it ethical to profit from obesity treatment?

This question comes up a lot. My take: You’re not ‘profiting from obesity’ — you’re providing a medical service that improves health outcomes. Obesity is a chronic disease with serious complications (diabetes, heart disease, joint problems, mental health impacts). Offering effective treatment is ethical and responsible. What would be unethical is exploiting patients with false promises, charging exorbitant fees for minimal care, or prescribing inappropriately for profit. Treat patients the way you’d want your family treated, and you’re on solid ground.

Sources and References

1. Dr. Alex Spencer (Metabolic Psychiatrist) – Should Psychiatrists Prescribe GLP-1s? DrLewis.com, January 4, 2026. https://drlewis.com/glp-1-medications-psychiatry/

2. Bask Health – Persona Marketing for GLP-1 Weight Loss. Bask Health Blog, January 2, 2026. https://bask.health/blog/glp-1-weight-loss-persona-marketing

3. Kaiser Family Foundation (KFF) – Medicaid Coverage of and Spending on New Drugs Used for Weight Loss. KFF Policy Watch, January 16, 2026. https://www.kff.org/policy-watch/medicaid-coverage-of-and-spending-on-new-drugs-used-for-weight-loss/

4. Real Chemistry – State-by-State Analysis of Medicaid Coverage for GLP-1 Weight Loss. Real Chemistry Reports, December 15, 2024 (updated January 2, 2025). https://www.realchemistry.com/state-by-state-analysis-of-medicaid-coverage-for-glp-1-weight-loss

5. Marketdata LLC – $6.9 Billion Weight Loss Telehealth Market Grows But Gets Crowded. Market Research Blog, April 16, 2024. https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded

Source:

• https://bask.health/blog/glp-1-weight-loss-persona-marketing#:~:text=movement%20that%20changes%20healthcare
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=consumers%20like%20the%20convenience
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=I%20want%20to%20address%20a,1%20receptor%20agonist%20medications
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=%2A%20GLP,1s%20as%20part%20of%20integrated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=neurotransmitter%20function%20,psychiatric%20care
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=Traditionally%2C%20psychiatrists%20prescribe%20psychiatric%20medications,primarily%20indicated%20for%20metabolic%20conditions
• https://blog.marketresearch.com/6.9-billion-weight-loss-telehealth-market-grows-but-gets-crowded#:~:text=Top%20Things%20to%20Know%20About,Weight%20Loss%20Telehealth%20Services
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=Major%20Players%3A%20Digital%20health%20companies,and%20independent%20provider%20practices
• https://www.tactionsoft.com/blog/glp-1-virtual-clinic/#:~:text=,independent%20provider%20practices
• https://www.statnews.com/2025/11/18/telehealth-pharma-glp1-partnerships-increase-drug-access-boost-sales/#:~:text=Patients%20searching%20for%20those%20deals,that%20partner%20with%20Novo%20Nordisk